Crystallization of a non-B and a B mutant HIV protease

Acta Crystallogr D Biol Crystallogr. 2004 Sep;60(Pt 9):1625-7. doi: 10.1107/S0907444904015276. Epub 2004 Aug 26.

Abstract

HIV polymorphism is responsible for the selection of variant viruses resistant to inhibitors used in AIDS treatment. Knowledge of the mechanism of resistance of those viruses is determinant to the development of new inhibitors able to stop, or at least slow down, the disease's progress caused by new mutations. In this paper, the crystallization and preliminary crystallographic structure solution for two multi-resistant 99 amino acid HIV proteases, both isolated from Brazilian patients failing intensive anti-AIDS therapy are presented, viz. the subtype B mutant, with mutations Q7K, S37N, R41K, K45R, I54V, L63P, A71V, V82A and L90M, and the subtype F (wild type), naturally carrying mutations Q7K, I15V, E35D, M36I, S37N, R41K, R57K, D60E, Q61N, I62V, L63S, I64L and L89M, with respect to the B consensus sequence. Both proteins crystallized as a complex with the inhibitor TL-3 in space group P6(1)22. X-ray diffraction data were collected from these crystals to resolutions of 2.1 and 2.6 A for the subtype B mutant and subtype F wild type, respectively, and the enzyme structures were solved by molecular replacement. The crystals of subtype F HIV protease are, to the best of the authors' knowledge, the first protein crystals obtained for a non-B HIV protease.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Crystallization
  • Crystallography, X-Ray
  • Data Interpretation, Statistical
  • Drug Resistance, Viral
  • HIV Protease / biosynthesis
  • HIV Protease / chemistry*
  • HIV Protease / isolation & purification
  • Humans
  • Isoenzymes / biosynthesis
  • Isoenzymes / chemistry
  • Isoenzymes / isolation & purification
  • Molecular Weight
  • Protein Conformation
  • Protein Folding

Substances

  • Isoenzymes
  • HIV Protease